Former ABN Amro Funds invests
Amsterdam – Forbion capital has invested EUR30 million in the French biopharmaceutical company Fovea SA in Paris. Alongside Forbion, participants included the other investors, among them Sofinnova, Abingworth, GIMV, The Wellcome trust and CAPE. Fovea is developing a program for chronic allergic conjunctivitis that is moving into Phase II testing. Forbion Capital is a spin-off of ABN Amro Capital Life Sciences funds together with Coller Capital.